I agree that this site is using cookies. You can find further informations here.
X
Zhou, Cathy
252  results:
Search for persons X
?
1

Outcomes in Patients with High-Risk Features after Fixed-Du..:

Allan, John N. ; Flinn, Ian W. ; Siddiqi, Tanya...
Clinical Cancer Research.  29 (2023)  14 - p. 2593-2601 , 2023
Link: https://doi.org/10.1158/..
 
?
2

P617: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-..:

Ghia, Paolo ; Allan, John ; Siddiqi, Tanya...
HemaSphere.  7 (2023)  S3 - p. e2822842 , 2023
Link: https://doi.org/10.1097/..
 
?
3

Immune restoration with ibrutinib plus venetoclax in first-..:

Moreno, Carol ; Solman, Isabelle G. ; Tam, Constantine S....
Blood Advances.  7 (2023)  18 - p. 5294-5303 , 2023
Link: https://doi.org/10.1182/..
 
?
4

Effective Tumor Debulking with Ibrutinib Before Initiation ..:

Barr, Paul M. ; Tedeschi, Alessandra ; Wierda, William G....
Clinical Cancer Research.  28 (2022)  20 - p. 4385-4391 , 2022
Link: https://doi.org/10.1158/..
 
?
5

Fixed-duration ibrutinib plus venetoclax for first-line tre..:

Tam, Constantine S. ; Allan, John N. ; Siddiqi, Tanya...
Blood.  139 (2022)  22 - p. 3278-3289 , 2022
Link: https://doi.org/10.1182/..
 
?
6

Many People with Chronic Lymphocytic Leukemia or Small Lymp..:

Barr, Paul M ; Owen, Carolyn ; Robak, Tadeusz...
Future Oncology.  18 (2022)  37 - p. 4047-4057 , 2022
Link: https://doi.org/10.2217/..
 
?
7

Up to 8-year follow-up from RESONATE-2: first-line ibrutini..:

Barr, Paul M. ; Owen, Carolyn ; Robak, Tadeusz...
Blood Advances.  6 (2022)  11 - p. 3440-3450 , 2022
Link: https://doi.org/10.1182/..
 
?
8

Pretreatment with ibrutinib reduces cytokine secretion and ..:

Greil, Richard ; Tedeschi, Alessandra ; Moreno, Carol...
Annals of Hematology.  100 (2021)  7 - p. 1733-1742 , 2021
Link: https://doi.org/10.1007/..
 
?
9

Functional Adrenal Collision Tumor in a Patient with Cushin..:

Zhou, Cathy ; Fananapazir, Ghaneh ; Campbell, Michael J..
Case Reports in Endocrinology.  2020 (2020)  - p. 1-5 , 2020
Link: https://doi.org/10.1155/..
 
?
10

A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Co..:

Ramanathan, Ramesh K. ; Thomas, Gary W. ; Khorana, Alok A....
Oncology.  96 (2019)  4 - p. 217-222 , 2019
Link: https://doi.org/10.1159/..
 
?
11

Opportunistic body composition evaluation in patients with ..:

Zhou, Cathy ; Foster, Brent ; Hagge, Rosalie...
Annals of Nuclear Medicine.  34 (2019)  3 - p. 174-181 , 2019
Link: https://doi.org/10.1007/..
 
?
12

Tumour debulking and reduction in predicted risk of tumour ..:

Wierda, William G. ; Byrd, John C. ; O'Brien, Susan...
British Journal of Haematology.  186 (2019)  1 - p. 184-188 , 2019
Link: https://doi.org/10.1111/..
 
?
13

Characterizing the kinetics of lymphocytosis in patients wi..:

Barrientos, Jacqueline C. ; Burger, Jan A. ; Byrd, John C....
Leukemia & Lymphoma.  60 (2018)  4 - p. 1000-1005 , 2018
Link: https://doi.org/10.1080/..
 
?
14

Evaluation of 230 patients with relapsed/refractory deletio..:

Jones, Jeffrey ; Mato, Anthony ; Coutre, Steven...
British Journal of Haematology.  182 (2018)  4 - p. 504-512 , 2018
Link: https://doi.org/10.1111/..
 
?
15

Clinical utility of tumor genomic profiling in patients wit..:

Zhou, Cathy ; Yuan, Zilong ; Ma, Weijie...
Journal of Hematology & Oncology.  11 (2018)  1 - p. , 2018
Link: https://doi.org/10.1186/..
 
1-15